Research Article| Volume 378, P233-237, July 15, 2017

Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?


      • The beneficial use of maraviroc in PML is still anecdotal.
      • Three Italian PML cases treated with maraviroc are described.
      • Data are interpreted in light of the Italian national database.
      • Data do not support the beneficial use of maraviroc in PML and PML-IRIS.
      • Clinical stabilization of patients with PML-IRIS was evident only after steroids use.



      Despite the recent advances in the understanding of natalizumab (NTZ) related progressive multifocal leukoencephalopathy (PML) and its associated immune reconstitution inflammatory syndrome (PML-IRIS), the therapeutic options are still under investigated. In this context, the beneficial use of maraviroc is still an anecdotal observation.


      To evaluate the impact of maraviroc in modifying the course of PML preventing IRIS or blunting IRIS manifestations.


      Three patients with NTZ PML included in the Italian dataset of PML were treated with maraviroc. Their longitudinal clinical and radiological course was described in detail.


      The three patients were characterized by a steady clinical worsening not controlled by maraviroc. All the three patients manifested PML-IRIS, which emerged, respectively, at 62, 64 and 90 days post NTZ withdrawal. This is in accordance with the data of the Italian dataset. Clinical and radiological stabilization of PML-IRIS occurred only after corticosteroids administration.


      In these three cases, maraviroc did not show any clear effect in modulating the clinical course of PML preventing IRIS. Moreover, once PML-IRIS emerged, the clinical stabilization was achieved only with the use of corticosteroids. Thus, the use of maraviroc should be regarded with extreme caution due the potential adverse events associated with its use.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Clifford D.B.
        Progressive multifocal leukoencephalopathy therapy.
        J. Neuro-Oncol. 2015; 21: 623-636
        • Berger J.R.
        Classifying PML risk with disease modifying therapies.
        Mult. Scler. Relat. Disord. 2017; 12: 59-63
        • Aly L.
        • Yousef S.
        • Schippling S.
        • et al.
        Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.
        Brain. 2011; 134: 2687-2702
        • Antoniol C.
        • Jilek S.
        • Schluep M.
        • et al.
        Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?.
        Neurology. 2012; 79: 2258-2264
        • Giacomini P.S.
        • Rozenberg A.
        • Metz I.
        • et al.
        Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome.
        N. Engl. J. Med. 2014; 370: 486-488
        • Martin-Blondel G.
        • Brassat D.
        • Bauer J.
        • et al.
        CCR5 blockage for neuroinflammatory diseases-beyond control of HIV.
        Nat. Rev. Neurol. 2016; 12: 95-105
        • Griffith J.W.
        • Sokol C.L.
        • Luster A.D.
        • et al.
        Chemokines and chemokine receptors: positioning cells for host defense and immunity.
        Annu. Rev. Immunol. 2014; 32: 659-702
        • Bseth G.
        • Auer M.
        • Igsleder S.
        • et al.
        Severe early natalizumab-associated PML in MS: effective control of PML-IRIS with Maraviroc.
        Neurol. Neuroimmunol. NeuroInflamm. 2017; 4: e323
        • Hodecker S.C.
        • Stuner K.H.
        • Becker V.
        Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS.
        Neurol. Neuroimmunol. NeuroInflamm. 2017; 4: e325
        • Prosperini L.
        • De Rossi N.
        • Scarpazza C.
        • et al.
        Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: findings from an Italian independent registry.
        PLoS One. 2016; 11: e0168376
        • Berger J.R.
        • Aksamit A.J.
        • Clifford D.B.
        • et al.
        PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.
        Neurology. 2013; 80: 1430-1438
        • Kurtzke J.F.
        Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
        Neurology. 1983; 33: 1444-1452
        • Karnofsky D.A.
        • Burchenal J.H.
        The clinical evaluation of chemotherapeutic agents in cancer.
        in: CM MacLeod Evaluation of Chemotherapeutic Agents. Columbia University Press, New York1949: 191-205
        • Sierra-Madero J.G.
        • Ellengerg S.S.
        • Rassool M.
        • et al.
        Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomized, placebo-controlled trial.
        Lancet HIV. 2014; 1: e60-e67
        • Scarpazza C.
        • De Rossi N.
        • Prosperini L.
        • et al.
        To do or not to do? Plasma exchange and steroids in progressive multifocal leukoencephalopathy management.
        in: 32nd Congress of ECTRIMS. Free Communications Session, Power Point presentation. 2016 (Available from:)
        • Gagne Brosseau M.S.
        • Stobbe G.
        • Wundes A.
        • et al.
        Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay.
        Neurology. 2016; 86: 1-3
        • Dong-Si T.
        • Gheuns S.
        • Gangadharan A.
        • et al.
        Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
        J. Neuro-Oncol. 2015; 21: 637-644
        • Martin-Blondel G.
        • Bauer J.
        • Cuvinciuc V.
        • et al.
        In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infection.
        Neurology. 2013; 81: 964-970
        • Martin-Blondel G.
        • Bauer J.
        • Uro-Coste E.
        • et al.
        Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8(+) T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome.
        Acta Neuropathol. 2015; 129: 463-465
        • Woollard S.M.
        • Kanmogne D.G.
        Maraviroc: a review of its use in HIV infection and beyond.
        Drug Des. Devel. Ther. 2015; 9: 5447-5468
        • Steiner I.
        • Benninger F.
        Maraviroc in PML-IRIS. A separate ball game under HIV infection and natalizumab?.
        Neurol. Neuroimmunol. NeuroInflamm. 2017; 4: e331

      Linked Article